SIC
HZNP

Samalin Investment Counsel’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Samalin Investment Counsel’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,680
Closed -$1M – 284
2023
Q3 		$1M Sell
8,680
-169
-2% -$18.2K 0.58% 45
2023
Q2 		$910K Buy
+8,849
New +$934K 0.49% 51

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Samalin Investment Counsel's HZNP Position: Q4 2023 in Review

Samalin Investment Counsel sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 8,680 shares — an estimated $1M sold.

Samalin Investment Counsel first reported a position in HZNP in Q2 2023 and held it in 2 quarters. The position peaked at $1M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Samalin Investment Counsel reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Samalin Investment Counsel sold 8,680 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1M.
  • Samalin Investment Counsel first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 2 quarters.
  • Samalin Investment Counsel's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Samalin Investment Counsel's 13F filing for Q4 2023, filed 14 Feb 2024.